A selection of the companies we support.
Advanced Prodrug Technologies
PharmaCytics’ proprietary platform technology improves PK properties of small molecules of both R&D and marketed compounds. PharmaCytics focuses on increasing the oral bioavailability and thereby turning a parenteral compound into an effective oral variant. The technology creates an NCE and may thus contribute to the life cycle management plans of companies.
For patients, this renders a drug with a preferred route of administration and with less side effects and higher efficacy. For society on a whole, it leads to a significant decrease in health care costs.
Cancer immunotherapy for solid tumors
CimCure develops a vaccination based immunotherapy directed against the tumor blood vessels that are common to most solid tumors.
Pharmatide is lead investor in Cimcure’s pre-seed financing round, a friends and family round that is expected to close in short notice. Subsequently, Pharmatide will also lead the next financing round, which is expected to be finalized in 2021.